CJC-1295
Phase II TrialsAlso known as: DAC:GRF, CJC-1295 with DAC
Educational Content Only
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.
CJC-1295 is a synthetic analogue of GHRH with a drug affinity complex (DAC) modification that extends its half-life significantly. It has been studied for sustained stimulation of growth hormone and IGF-1 levels in clinical trials.
The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.
- Muscle Recovery & Repair
- Growth Hormone Regulation
- Fat Loss & Metabolism
- Anti-Aging & Longevity
Binds to GHRH receptors in the pituitary. The DAC modification allows covalent binding to albumin, dramatically extending the biological half-life from minutes to days.
Phase II clinical trials have been conducted. Not FDA-approved. The extended half-life raises considerations about hormonal feedback disruption.
Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL et al. (2006). Journal of Clinical Endocrinology & Metabolism.DOI: 10.1210/jc.2005-1536
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Ionescu M, Frohman LA. (2006). Journal of Clinical Endocrinology & Metabolism.
Want to learn more?
Ask Research Chat about CJC-1295Half-Life
~6-8 days (with DAC)
Administration
subcutaneous injection
Legal Status (US)
Research chemical in the US. Not FDA-approved.
59 indexed research passages
Related Peptides
GHRP-2 (pralmorelin) is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate pulsatile GH release through the ghrelin receptor. It has been investigated in clinical studies and is sometimes used diagnostically for growth hormone deficiency assessment in some countries.
Hexarelin is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate GH release and its potential cardioprotective effects in animal models and early human studies.
IGF-1 (insulin-like growth factor 1) is an endogenous polypeptide hormone critical for growth, development, and metabolic homeostasis. It is produced primarily in the liver in response to GH signaling and acts through IGF-1 receptors on virtually all tissues. Recombinant IGF-1 (mecasermin) is FDA-approved for children with severe primary IGF-1 deficiency.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification to improve stability. It is FDA-approved for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients receiving antiretroviral therapy, and has been studied for cognitive function in aging.